Additionally, flecainide was reported to block calcium release channel, ryanodine receptor-2 (RyR2), and thereby suppress calcium waves in cardiomyocytes and prevent catecholaminergic polymorphic ventricular tachycardia in mice and humans (Watanabe et al., 2009). This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.